VVOS

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.

Wall Street analysts forecast VVOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VVOS is 6.75 USD with a low forecast of 6.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vivos Therapeutics Inc revenue for the last quarter amounts to 6.78M USD, increased 75.73 % YoY.

Vivos Therapeutics Inc. EPS for the last quarter amounts to -0.49 USD, increased 22.50 % YoY.

Vivos Therapeutics Inc (VVOS) has 109 emplpoyees as of January 10 2026.

Today VVOS has the market capitalization of 19.11M USD.